Global Huntington’s Disease Drugs Market Forecast 2018-2028 : Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules

ハンチントン病治療薬の世界市場2018-2028

◆タイトル:Global Huntington’s Disease Drugs Market Forecast 2018-2028 : Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules
◆商品コード:VGAIN803036
◆調査・発行会社:visiongain
◆発行日:2018年1月
◆ページ数:163
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥399,452見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、ハンチントン病治療薬の世界市場について調査・分析し、ハンチントン病治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・ハンチントン病治療薬のイントロダクション
・世界におけるハンチントン病治療薬市場規模と予測:治療薬クラス別
・世界におけるハンチントン病治療薬市場の主要薬2017
・主要国における市場予測2017-2028
・ハンチントン病治療薬市場の品質分析
・パイプライン分子
・世界におけるハンチントン病治療薬市場の主要企業2017
・エグゼクティブサマリー・提言
・用語集

Report Details
• Do you need definitive Huntington’s Disease market data?
• Succinct Huntington’s Disease market analysis?
• Technological insight?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The Global Huntington’s Disease market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.
Lastly, the study of the pathogenesis of disease at genetic and molecular level have led to the discovery of new targets for therapy and producing disease modifying drugs.

Report highlights
• 77 quantitative tables, charts, and graphs across 163 pages

• Global Huntington’s Disease market outlook and analysis from 2018-2028

• Global Huntington’s Disease submarket forecasts and analysis from 2018-2028
• Antidopaminergics
• Antipsychotics
• Anticonvulsants
• Antidepressants
• Other

• Regional and National Huntington’s Disease market forecasts 2018-2028
• North America forecast 2018-2028
• US forecast 2018-2028
• Rest of North America forecast 2018-2028

• Europe forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Rest of Europe forecast 2018-2028
• Rest of World forecast 2018-2028

【レポートの目次】

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Key Questions Answered by This Analytical Report Include:
1.4 Who is This Report For?
1.5 Methodology
1.5.1 Primary Research
1.5.2 Secondary Research
1.5.3 Market Evaluation & Forecasting Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Huntington’s Disease
2.1 What Are the Causes And Risk Factors Of Huntington’s Disease?
2.1.1 Risk Factors
2.1.1.1 Alcohol Intake
2.1.1.2 Pneumonia:
2.1.1.3 Stress
2.2 Symptoms of Huntington’s Disease
2.2.1 Symptoms in Adult Onset
2.2.2 Movement Disorders
2.2.3 Cognitive Disorders
2.2.4 Psychiatric Disorders
2.2.5 Symptoms in Juvenile Onset
2.2.6 Behavioural Changes:
2.3 Diagnosis of Huntington’s Disease
2.3.1 Neurological Tests:
2.3.2 Brain Function and Imaging Tests:
2.3.3 Genetic Testing:
2.3.4 Psychiatric Tests:
2.3.5 Test in Pregnancy:
2.3.6 Preimplantation Genetic Diagnosis:
2.4 Treatment of Huntington’s Disease
2.4.1 Medications for Movement Disorders:
2.4.2 Medications for Psychiatric Disorders:
2.4.3 Psychotherapy
2.4.4 Speech Therapy
2.4.5 Physical Therapy
2.4.6 Occupational Therapy
2.5 Epidemiology of Huntington’s Disease
2.6 Social and Economic Burden
2.6.1 Mortality
2.6.2 Morbidity
2.6.3 Economic Impact
2.7 Introduction to the Global Huntington’s Disease Market

3. Global Huntington’s Disease Market Size And Forecast By Drug Class
3.1 Market Segmentation by Application
3.2 Global Antidopaminergics Market
3.2.1 Market Overview
3.2.2 Market Size and Forecast
3.3 Global Antipsychotics Market
3.3.1 Market Overview
3.3.2 Market Size and Forecast
3.4 Global Anticonvulsants Market
3.4.1 Market Overview
3.4.2 Market Size and Forecast
3.5 Global Antidepressants Market
3.5.1 Market Overview
3.5.2 Market Size and Forecast
3.6 Global Other Huntington’s Disease Drugs Market
3.6.1 Market Overview
3.6.2 Market Size and Forecast

4. Leading Drugs in Global Huntington’s Disease Market, 2017
4.1 Xenazine (tetrabenazine)
4.2 Austedo (Deutetrabenazine)
4.3 Clozapine
4.4 Haloperidol
4.5 Abilify
4.6 Risperdal

5. Leading National Markets Forecast 2017-2028
5.1 Geographical Breakdown of Global Huntington’s Disease Drugs Market, 2016
5.2 Huntington’s Disease Drugs Market in the Americas, 2016
5.3 Huntington’s Disease Drugs Market in the EU5, 2016
5.3.1 Market Forecast of the EU5 Countries, 2017-2028
5.3.2 The UK
5.3.3 Germany
5.3.4 France
5.3.5 Spain
5.3.6 Italy
5.3.7 Huntington’s Disease Drugs Market in the Rest of Europe, 2016
5.4 Huntington’s Disease Drugs Market in the Rest of the World, 2016
5.4.1 Japan
5.4.2 China
5.4.3 Russia

6. Qualitative Analysis of the Huntington’s Disease Market
6.1 Market Growth Drivers
6.1.1 Unmet Medical Need
6.1.2 Special Regulatory Provisions for Rare Diseases
6.1.3 Designated ICD-10 Code
6.1.4 Increased investment in R&D
6.1.5 Alternative Therapies
6.2 Market Challenges
6.2.1 Poor Diagnosis Rates
6.2.2 Limited Patient Population
6.2.3 Stringent Regulatory Guidelines
6.2.4 Alternative programs for management of mental disorders
6.3 Market Trends
6.3.1 Advances in Biomedical Sciences
6.3.2 Focus on Regenerative Therapies for Mental Disorders
6.3.3 Rising Public Interest Toward Mental Health
6.3.4 Novel Mechanisms Targeted by Pipeline Candidates
6.3.5 Emergence of First-in-class Pipeline Molecules

7. Pipeline Molecules
7.1 Promising Potential Pipeline Molecules
7.1.1 Phase III Molecules
7.1.1.1 Tetrabenazine (Xenazine)
7.1.1.2 Deutetrabenazine (Austedo)
7.1.1.3 PRIDOPIDINE
7.1.2 Phase II Molecules
7.1.2.1 Laquinimod
7.1.2.2 PBT2
7.1.2.3 VX15 (SIGNAL)
7.1.2.4 PDE10A Inhibitor
7.1.2.5 Deep Brain Stimulation (DBS)
7.1.2.6 Cysteamine (RP103)
7.1.3 Phase I Molecules
7.1.3.1 Antisense Oligonucleotide Huntingtin Lowering Drug
7.1.4 Phase Pre-Clinical R&D
7.1.4.1 Pre- Cell/HD Cell
7.1.4.2 AAV-SHRNA
7.1.4.3 Zinc Finger DNA-Binding Protein (ZFP)
7.1.4.4 HDAC Inhibitor
7.1.4.5 KMO Inhibitor

8. Leading Companies in Global Huntington’s Disease Market, 2017
8.1 Hoffmann-La Roche Ltd.
8.1.1 SWOT Analysis:
8.2 H. Lundbeck
8.2.1 Business Strategy:
8.2.2 SWOT Analysis:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Business Strategy:
8.3.2 SWOT Analysis:
8.4 Prana Biotechnology
8.5 Sangamo Therapeutics Inc.
8.6 Horizon Pharma Plc.
8.6.1 Revenue from Business Units:
8.6.2 Business Strategy:
8.6.2.1 Key Developments:
8.6.2.2 SWOT Analysis:
8.7 Omeros Corp.
8.7.1 SWOT Analysis:
8.8 Valeant Pharmaceuticals International Inc.
8.8.1 Business strategy:
8.8.2 SWOT Analysis

9. Executive Summary and Recommendations

10. Glossary
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Figures
Figure 1.1 Example of Huntington’s Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.1 Example of Huntington’s Disease Market by Regional Market Share Forecast 2017, 2022, 2027(% Share)
Figure 2.2 Global Huntington’s Disease Market Segmentation by Drug Class (% Share)
Figure 3.1 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.2 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.3 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.4 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.5 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 3.6 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%)
Figure 5.1 Global Huntington’s Disease Drugs Market Segmentation by Region/Country
Figure 5.2 Global Huntington’s Disease Drugs Market by Region: Revenue ($m)
Figure 5.3 Global Huntington’s Disease Drugs Market by Region: Market Share 2016 (%)
Figure 5.4 Global Huntington’s Disease Drugs Market by Region: AGR 2017-2028 (%)
Figure 5.5 Global Huntington’s Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Figure 5.6 Global Huntington’s Disease Drugs Market by Region: Market Share Forecast 2017 (%)
Figure 5.7 Global Huntington’s Disease Drugs Market by Region: Market Share Forecast 2022 (%)
Figure 5.8 Global Huntington’s Disease Drugs Market by Region: Market Share Forecast 2027 (%)
Figure 5.9 Huntington’s Disease Drugs Market in the US: 2016 Market Share %
Figure 5.10 Huntington’s Disease Drugs Market in the US: 2016 Revenue ($m), Market Share %
Figure 5.11 Huntington’s Disease Market Forecast in the US 2017-2028: Revenue ($m), AGR (%)
Figure 5.12 Huntington’s Disease Drugs Market in the EU5 2016: Global Market Share (%)
Figure 5.13 Huntington’s Disease Drugs Market in the EU5 Countries 2016: Market Share (%)
Figure 5.14 Huntington’s Disease Drugs Market in the EU5 Countries 2028 Market Share (%)
Figure 5.15 Huntington’s Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2017-2028
Figure 5.16 Global Huntington’s Disease Drugs Market Forecast in The UK 2017-2028: Revenue ($m), AGR (%)
Figure 5.17 Global Huntington’s Disease Drugs Market Forecast in Germany 2017-2028: Revenue ($m), AGR (%)
Figure 5.18 Global Huntington’s Disease Drugs Market Forecast in France 2017-2028: Revenue ($m), AGR (%)
Figure 5.19 Global Huntington’s Disease Drugs Market Forecast in Spain 2017-2028: Revenue ($m), AGR (%)
Figure 5.20 Global Huntington’s Disease Drugs Market Forecast in Italy 2017-2028: Revenue ($m), AGR (%)
Figure 5.21 Huntington’s Disease Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2017-2028
Figure 5.22 Huntington’s Disease Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2017-2028
Figure 8.1: Roche: Sales 2016
Figure 8.2: Roche: Sales 2016
Figure 8.3: H. Lundbeck: SWOT Analysis 2016
Figure 8.4 Teva: SWOT Analysis 2016
Figure 8.5 Horizon Revenue by Business Unit
Figure 8.6 Horizon: Drugs under Orphan Business Unit:
Figure 8.7 Horizon Drugs under Primary Care Unit:
Figure 8.8 Horizon: Drugs under Rheumatology Business Unit:
Figure 8.9 Horizon SWOT Analysis
Figure 8.10 Omeros Corp: SWOT Analysis
Figure 8.11 Valeant SWOT Analysis
Figure 9.1 Global Huntington’s Disease Market Forecast 2017-2028: Revenue ($m), AGR (%)

List of Tables
Table 1.1 Example of Huntington’s Disease Market by Regional Market Forecast 2017-2028 (US$m, AGR %, Cumulative)
Table 2.1: Prevalence of Huntington’s Disease by Geography 2015
Table 2.2: Incidence of Huntington’s Disease by Geography 2015
Table 3.1 Global Huntington’s Disease Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.2 Global Antidopaminergics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.3 Global Antipsychotics Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.4 Global Anticonvulsants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.5 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 3.6 Global Antidepressants Drugs Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
Table 5.1 Global Huntington’s Disease Drugs Market by Region: Revenue ($m), and Market Share (%), 2016
Table 5.2 Global Huntington’s Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.3 Global Huntington’s Disease Drugs Market by Region: AGR 2017-2028 (%)
Table 5.4 Global Huntington’s Disease Drugs Market by Region: Market Share Forecast 2017-2028 (%)
Table 5.7 Global Huntington’s Disease Drugs Market Forecast in the Americas: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.8 Global Huntington’s Disease Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%),2017-2028
Table 5.9 Huntington’s Disease Drugs Market in the EU5, 2017
Table 5.10 Huntington’s Disease Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.11 Huntington’s Disease Drugs Market Forecast in UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.12 Huntington’s Disease Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.13 Huntington’s Disease Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.14 Huntington’s Disease Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.15 Huntington’s Disease Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.16 Huntington’s Disease Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 5.17 Huntington’s Disease Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2017-2028
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington’s Disease
Table 7.1: Active Pipeline Molecules under Development for Treating Huntington’s Disease (Continued)
Table 8.1:Roche: Overview 2016
Table 8.2: H. Lundbeck: Overview 2016
Table 8.3: Teva: Overview 2016
Table 8.4 Prana: Overview 2016
Table 8.5: Sangamo: Overview 2016
Table 8.6: Horizon: Overview 2016
Table 8.7: Omeros: Overview 2016
Table 8.8: Valeant: Overview 2016



★調査レポート[ハンチントン病治療薬の世界市場2018-2028] ( Global Huntington’s Disease Drugs Market Forecast 2018-2028 : Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules / VGAIN803036) 販売に関する免責事項
[ハンチントン病治療薬の世界市場2018-2028] ( Global Huntington’s Disease Drugs Market Forecast 2018-2028 : Forecasts by Drug Class (Antidopaminergics, Antipsychotics, Anticonvulsants, Antidepressants, Other) and Geography, with Analysis for Leading Drugs (Xenazine, Austedo, Clozapine, Haloperidol, Abilify), Leading Companies and Promising Pipeline Molecules / VGAIN803036) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆